Shares of ProNAi Therapeutics Inc. (NASDAQ:DNAI) saw an uptick in trading volume on Wednesday . 1,386,051 shares were traded during trading, an increase of 63% from the previous session’s volume of 847,945 shares.The stock last traded at $2.02 and had previously closed at $1.96.

Several research firms recently issued reports on DNAI. Zacks Investment Research lowered ProNAi Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, May 4th. Wedbush reaffirmed an “outperform” rating and set a $36.00 price target on shares of ProNAi Therapeutics in a research note on Friday, May 27th. Jefferies Group reaffirmed a “buy” rating on shares of ProNAi Therapeutics in a research note on Sunday, May 29th. Finally, SunTrust Banks Inc. lowered ProNAi Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $25.00 to $4.00 in a research note on Monday, June 6th.

The stock has a 50 day moving average of $1.98 and a 200 day moving average of $4.47. The stock’s market capitalization is $57.77 million.

ProNAi Therapeutics (NASDAQ:DNAI) last released its quarterly earnings results on Friday, August 12th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.38) by $0.05. On average, equities research analysts forecast that ProNAi Therapeutics Inc. will post ($1.32) EPS for the current year.

A hedge fund recently raised its stake in ProNAi Therapeutics stock. RS Investment Management Co. LLC increased its stake in ProNAi Therapeutics Inc. (NASDAQ:DNAI) by 12.3% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 699,794 shares of the company’s stock after buying an additional 76,550 shares during the period. RS Investment Management Co. LLC owned approximately 2.33% of ProNAi Therapeutics worth $10,525,000 at the end of the most recent quarter.

ProNAi Therapeutics, Inc is a clinical-stage oncology company. The Company is engaged in business of researching, developing and commercializing therapies for the treatment of patients with cancer and hematological diseases based on its deoxyribonucleic acid interference (DNAi) technology platform. Its lead product candidate includes PNT2258, which targets cancers that overexpress B-cell lymphoma 2 (BCL2), an oncogene known to be dysregulated in various types of cancer.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.